Cyclosporin A Following Matched and Mismatched Family Allogeneic Bone Marrow Transplants

Following the use of Cyclosporin A (CSA) in patients with established acute graft versushost disease (GVHD) [1] we initiated a study of CSA to prevent GVHD, because it seemed probable that it would be more effective in this role than for reversing the established process. We initially reported the results of 20 patients who had received matched allogeneic sibling bone marrow transplants and prophylactic CSA for longer than 3 months, only one of whom died of GVHD [2].